HEALTH MATTERS
A digest of medical and scientific news - July 2026
In this issue: an escalating Bundibugyo Ebola emergency and the first trials of treatments and vaccines against it; the close of the cruise-ship hantavirus cluster; a summer heat-health alert and the unequal geography of heat mortality; the extension of gene-editing therapy to young children with sickle cell disease; a landmark step towards a finite cure for hepatitis B; Britain’s first One Health surveillance of a changing vector-borne disease environment; and a sobering decade-on verdict on children’s health in the UK.
EBOLA · GLOBAL HEALTH SECURITY
The Bundibugyo virus emergency covered last month has continued to grow. By 4 July the Democratic Republic of the Congo had recorded 1,561 confirmed cases and 506 deaths2, with Ituri province worst affected; Uganda has confirmed 20 cases and two deaths, and France reported a single imported case in a returning doctor on 24 June1.
This is the first Bundibugyo outbreak in which patients are being enrolled in a randomised treatment trial3, the WHO-sponsored PARTNERS protocol is testing remdesivir, a broad-spectrum antiviral drug used in the treatment of severe COVID-19), and the monoclonal antibodies MBP-134 and maftivimab, while CEPI (The Coalition for Epidemic Preparedness Innovations) is fast-tracking three candidate vaccines, including one from the University of Oxford. There is still no licensed vaccine or drug treatment5 for this virus; the only approved methods were developed against the Zaire ebolavirus.
The outbreak is spreading through conflict-affected, displaced and mining communities with fragile health systems, and healthcare workers are among the infected.
The UK has deployed its Public Health Rapid Support Team4 and pledged £20 million, a reminder that countermeasure development for ‘neglected’ filoviruses depends on external investment and aid.
UPDATE · INFECTIOUS DISEASE
The last contact of the cruise-ship hantavirus cluster has completed quarantine, and returned home6, and with no new cases since 25 May the World Health Organisation now considers the outbreak over.
A total of 13 cases were recorded (12 confirmed and one probable), including three deaths. The episode usefully tested cross-border maritime health governance: passengers dispersing to multiple countries, a 42-day monitoring window and reliance on national quarantine capacity.
The MV Hondius outbreak was a rarity; hantavirus disease worldwide usually involves rural, agricultural and lower-income populations exposed to rodent reservoirs through poor-quality housing and occupational contact.
With surveillance now stood down, the lasting lesson is the value of rapid contact tracing and transparent international reporting in containing a pathogen for which there is no specific treatment. This requires adequate funding which, shortsightedly, has been reduced by some governments.
ENVIRONMENT · CLIMATE & HEALTH
As the time of writing, the UKHSA and Met Office have issued amber heat-health alerts7 for the East and West Midlands, the East of England, London and the South East and South West, with yellow alerts across the North, in force from 8 to 12 July.
The amber warning means that health effects are likely across the whole population, not just the clinically vulnerable, with subsequent rising pressure on health and social care. Heat is one of the most predictable and preventable climate-related killers; it is particularly dangerous for the disadvantaged, older and isolated people, and those with cardiovascular, respiratory and mental-health conditions8, and residents of deprived urban neighbourhoods with less green space, poorer-quality, harder to cool housing, and greater exposure to the urban heat-island effect.
Outdoor and manual workers in construction, agriculture and logistics, have an occupational exposure that is rarely publicly discussed. Suggesting that hot weather is a lifestyle inconvenience hides the underlying reality that the people who contribute least to the emissions which drive more frequent heat episodes are the least able to protect themselves from the consequences.
CLINICAL · GENOMIC MEDICINE & EQUITY
Regulators have extended the CRISPR gene-editing therapy Casgevy (exagamglogene autotemcel) to children as young as two9 with severe sickle cell disease or transfusion-dependent beta thalassaemia, lowering the age threshold for one-time curative gene editing.
The UK MHRA (Medicines and Healthcare products Regulatory Agency) was the first regulator in the world to clear the therapy, in November 2023. For a condition that in the UK affects mainly people of African and Caribbean heritage, a potential cure in early childhood is genuinely transformative.
However, Casgevy is a multimillion-dollar, technically demanding therapy requiring myeloablative therapy (bone marrow destruction) and specialist transplant facilities. The overwhelming majority of the world’s sickle cell births occur in sub-Saharan Africa, where such facilities are rarely available, so a disease concentrated in the Global South acquires a cure concentrated in a handful of wealthy health systems.
Widening access will depend on manufacturing scale-up, pricing and the political will to treat curative genomic medicine as a global-health priority.
CLINICAL · INFECTIOUS DISEASE
Twin phase 3 trials have delivered the most encouraging hepatitis B results in a long while.
In the B-Well 1 and B-Well 2 studies, published in the New England Journal of Medicine10, a finite 24-week course of the antisense oligonucleotide bepirovirsen produced a functional cure in roughly one in five patients (20% and 19%) at week 72 after stopping standard antiviral therapy, versus none on placebo, across 1,834 participants in 29 countries. ‘Functional cure’ means sustained loss of hepatitis B surface antigen with undetectable viral DNA — not eradication, but freedom from lifelong daily medication.
The British Liver Trust14 has called it an encouraging step after decades of stagnation. Chronic hepatitis B affects an estimated 250–300 million people worldwide11, with the worst affected areas being the Western Pacific and sub-Saharan Africa, where lifelong therapy and monitoring are hardest to maintain.
A short, curative-intent regimen could be far better suited to low-resource settings, but only if pricing and supply are designed for the countries most affected, rather than the markets that can pay most.
Regulatory decisions are expected later in 2026.
ENVIRONMENT · ONE HEALTH & ZOONOSES
The UKHSA, Defra and the Animal and Plant Health Agency have published the first annual One Health Vector-Borne Disease Surveillance report12, integrating human, animal and environmental data for the first time.
Lyme disease remains the commonest locally acquired vector-borne infection in the UK, with 1,168 laboratory-confirmed acute cases in 2025, while tick-borne encephalitis13, absent from Britain until 2019, has now produced six locally acquired human cases, two of them in 2025. West Nile virus was detected in UK mosquitoes for the first time in 2023, and Usutu virus is now considered endemic in birds and mosquitoes in south-east England.
Warmer, wetter winters and longer tick seasons are steadily reshaping disease distribution. The One Health approach is important because human, veterinary and ecological health are not separable problems. They are part of the same system.
Co-ordinated surveillance, tracking pathogens in deer and mosquitoes before they surface in people, is the kind of upstream, preventive approach that is required if we are to successfully control these vector-borne diseases.
A reduction in greenhouse gasses would help as well.
SOCIAL MEDICINE · CHILD HEALTH & INEQUALITY
The Royal College of Paediatrics and Child Health has published its decade-on update to State of Child Health15, and the verdict is bleak. Across all 12 indicators, including infant mortality, immunisation, obesity, asthma, mental health, and oral health - children’s health in the UK has either declined or stalled since the first report in 2017.
Only 84% of children receive two doses of MMR by age five, well short of the WHO’s 95% target and the worst performance in the G7; more than one in three 10 to 11-year-olds is overweight or obese; and around one in five children aged 8 to 16 has a probable mental health disorder16. Infant mortality remains at 4.1 per 1,000 and above comparable European countries17.
Infant mortality in the most deprived communities is more than double that in the least deprived, and children in the poorest areas are four times more likely to die from asthma, an eminently treatable condition.
Dr Helen Stewart, RCPCH officer for health improvement, called the UK’s record a national embarrassment18, noting that children from ethnic minority and poorer backgrounds are being failed most comprehensively.
The College attributes the picture to widening inequality and chronic under-investment, and is pressing the incoming government for fair and consistent investment in children’s services and workforce, better UK-wide data collection, and binding national targets to narrow the gap between richest and poorest.
This not primarily a failure of medicine. Asthma deaths, dental extractions and unimmunised children are related to housing quality, air pollution, food environments and household income, and no amount of paediatric capacity will substitute for acting on these factors.
References
1. World Health Organization. Disease Outbreak News: Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo and Uganda. 3 July 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON612
2. European Centre for Disease Prevention and Control. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda. 6 July 2026. https://www.ecdc.europa.eu/en/ebola-outbreak-democratic-republic-congo-and-uganda
3. World Health Organization. Ebola outbreak – DRC 2026 (PARTNERS trial and response). https://www.who.int/emergencies/situations/ebola-outbreak---drc-2026
4. UK Health Security Agency. GOV.UK organisation page (UK-PHRST deployment). https://www.gov.uk/government/organisations/uk-health-security-agency
5. Médecins Sans Frontières. Bundibugyo virus: why this Ebola disease outbreak is different. 2026. https://www.doctorswithoutborders.org/latest/bundibugyo-virus-why-ebola-disease-outbreak-different
6. NaTHNaC / TravelHealthPro. Outbreak surveillance (hantavirus, MV Hondius). 2026. https://travelhealthpro.org.uk/outbreaks
7. UK Health Security Agency. Weather-health alerts / UKHSA data dashboard. July 2026.
https://ukhsa-dashboard.data.gov.uk/
8. UK Health Security Agency. Staying safe in hot weather (Public health matters blog). June 2026.
https://ukhsa.blog.gov.uk/
9. Healthcare News Roundup: FDA, NHS and EMA decisions (Casgevy paediatric approval). July 2026. https://healthcarereaders.com/news/healthcare-news-27th-june-to-4th-july-2026
10. Hou J, Lim SG, Buti M, et al. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N Engl J Med. 2026;394(24):2395–2406. https://www.nejm.org/doi/full/10.1056/NEJMoa2515131
11. GSK. Bepirovirsen achieves unprecedented functional cure rates for chronic hepatitis B. 28 May 2026. https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/
12. UKHSA, Defra and APHA. First annual One Health Vector-Borne Disease Surveillance report. 2026. https://www.gov.uk/government/news/ukhsa-and-partners-publish-first-one-health-annual-vector-borne-disease-surveillance-report
13. UK Health Security Agency. What is tick-borne encephalitis virus and is it found in the UK? (blog). 21 May 2026. https://ukhsa.blog.gov.uk/2026/05/21/what-is-tick-borne-encephalitis-virus-and-is-it-found-in-the-uk/
14. Hospital Healthcare Europe. Bepirovirsen delivers ‘functional cure’ for chronic hepatitis B (British Liver Trust comment). 2026. https://hospitalhealthcare.com/specialisms/gastroenterology/bepirovirsen-delivers-functional-cure-for-chronic-hepatitis-b-virus-infections-phase-3-trials-show/
15. Royal College of Paediatrics and Child Health. The UK is raising one of the unhealthiest generations in decades, paediatricians warn. July 2026. https://www.rcpch.ac.uk/news-events/news/2026-07/uk-raising-one-unhealthiest-generations-decades-paediatricians-warn
16. Royal College of Paediatrics and Child Health. State of Child Health 2026: about our report. https://stateofchildhealth.rcpch.ac.uk/evidence/nations/england/
17. Royal College of Paediatrics and Child Health. State of Child Health 2026: Infant mortality. https://www.rcpch.ac.uk/work-we-do/state-of-child-health/infant-mortality
18. Healthcare Management. UK ‘sick man of Europe’ on children’s health, report reveals. July 2026. https://www.healthcare-management.uk/uk-sick-man-europe-children-health-report-reveals